Home

Robert James Wills

CIK 1634189 · Executive Chairman · last filed 2026-08-24

Robert James Wills is an Executive Chairman who has filed 50 SEC Form 4 insider transactions across 5 companies since 2015. The most recent filing shows the insider bought $96.2K of ACOG on Aug 24, 2026. Across all open-market trades the lifetime net is +$706.4K, making them a net buyer over the disclosed history. Current disclosed insider exposure totals $350.7K across reported positions.

"Disclosed insider exposure" sums this person's most-recently-reported share counts across each company they're an insider in, multiplied by the current underlying price. It is not net worth — it misses retail holdings, private investments, real estate, index funds, and any company where the person isn't an SEC-reporting insider. For informational purposes only.

Loading insider history…
Disclosed Exposure

$350.7K

Companies

5

Total Filings

50

Lifetime Open-Market Net

$706.4K

Filer Profile

Reported Address
204 SOUTH BOULEVARD
SPRING LAKE, NJ 07762
Profile details as reported on the filer's SEC submissions — for individual insiders the address is often in care of the issuer. Related filers are identified from jointly filed SEC submissions and shared reported addresses. View filings on SEC EDGAR.

Holdings By Company

Latest on-record share count from this person's most recent non-derivative Form 4 transaction in each company. Disclosed exposure = shares × current underlying price.
Symbol Role Shares Price Disclosed Exposure Lifetime OM Net Filings Latest Filed
ACOG Director 32,241 $8.90 $286.9K $223.5K 4 2026-08-24
MIST Director 65,000 $0.98 $63.7K $74.0K 9 2026-06-12
Oncternal Therapeutics, Inc. (ONCT) Delisted Director 10,000 $0.53 $5.3K $77.4K 11 2024-06-24
CymaBay Therapeutics, Inc. (CBAY) Delisted Director 0 $32.48 $0 $95.1K 16 2024-03-22
Oncternal Therapeutics, Inc. (GTXI) Delisted Executive Chairman 19,621 — — $236.4K 10 2018-06-26

Recent Filings

50 filings
Insider activity across all companies, newest first. Form 4 rows are post-trade confirmations (buys, sells, grants, exercises). Notice (144) rows are pre-trade notices of intent to sell restricted or control stock under Rule 144 — they may not all execute. Compare adjacent dates to see which notices became actual sales.
Filed Symbol Action Net Shares Net $ Link
2026-08-24 ACOG Buy (P) +10,000 $96.2K EDGAR
2026-06-12 MIST Grant (A) — $0 EDGAR
2026-01-16 ACOG Grant (A) +7,241 $0 EDGAR
2025-08-21 ACOG Buy (P) +15,000 $127.3K EDGAR
2025-07-15 MIST Grant (A) +50,000 $0 EDGAR
2025-06-12 MIST Grant (A) — $0 EDGAR
2025-04-09 ACOG Grant (A) — $0 EDGAR
2024-08-29 MIST Grant (A) — $0 EDGAR
2024-06-24 Oncternal Therapeutics, Inc. (ONCT) Delisted Grant (A) — $0 EDGAR
2024-04-10 Oncternal Therapeutics, Inc. (ONCT) Delisted Buy (P) +3,086 $27.7K EDGAR
Showing 1–10 of 50
Page 1 of 5
Form 4 codes: P = open-market purchase · S = open-market sale · A = grant/award · M = option exercise · F = tax withholding at vest · G = bona-fide gift · D = disposition to issuer · J = other (see filing footnote). Only P / S codes carry directional signal.
Notice (144 / 144/A): Form 144 is a notice of intent to sell restricted/control stock under Rule 144, filed before the sale; 144/A is an amendment. Many notices are pre-scheduled under Rule 10b5-1 plans. A Form 4 with code S typically follows within a few days when the planned sale executes; missing follow-up Form 4s suggest the notice was cancelled or modified.